HIV-1 PROTEASE CD4+ T CELL EPITOPES AND DRUG-INDUCED MUTATIONS

Information

  • Research Project
  • 7121321
  • ApplicationId
    7121321
  • Core Project Number
    R03AI066961
  • Full Project Number
    1R03AI066961-01A1
  • Serial Number
    66961
  • FOA Number
    PAS-04-111
  • Sub Project Id
  • Project Start Date
    4/1/2007 - 17 years ago
  • Project End Date
    3/31/2010 - 14 years ago
  • Program Officer Name
    LIVNAT, DANIELLA
  • Budget Start Date
    4/1/2007 - 17 years ago
  • Budget End Date
    3/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    3/13/2007 - 17 years ago
Organizations

HIV-1 PROTEASE CD4+ T CELL EPITOPES AND DRUG-INDUCED MUTATIONS

[unreadable] DESCRIPTION (provided by applicant): This R03 application aims at providing data in support of the underlying hypothesis that CD4+ T cell responses towards HIV-1 protease neoepitopes created by drug escape mutations can help to control the growth of resistant variants. A significant proportion of Pi-treated HIV-1 infected (HIV-1+) patients develop resistance mutations, and CD8+ T cell responses against such drug-induced mutant epitopes have been documented. It has been suggested that such a T cell response against epitopes under drug pressure may keep mutants under immunological control, or delay the emergence of drug resistance mutations, in patients undergoing antiretroviral (ARV) treatment. Given the importance of CD4+ T cell responses in maintaining CD8+ T cell memory, we will investigate, for the first time, the recognition of sites of Pi-induced mutations by CD4+ T cells of Pi-treated HIV-1 + patients. The study will have a cross-sectional (Aim 1) and a longitudinal arm (Aim 2). To search for CD4+ T cell responses against mutant protease epitopes (Aim 1), we will synthesize peptides representing wild-type and neoepitope sequences, incorporating major Pi-induced mutation sites and predicted to bind to multiple HLA-DR molecules in silico. To evaluate their promiscuity, we will assess their ability to bind multiple HLA-DR molecules in vitro. Subsequently, we will test the T cell responses from Pi-treated HIV-1 + patients to such peptides by IFN-gamma ELISPOT, CFSE proliferation and flow cytometry. Sequences of recognized peptides will be compared to endogenous HIV-1 protease sequence. In the longitudinal arm (Aim 2), we will study patients whose HIV-1 isolates developed new mutations in the protease gene along the 1-year observation period. Among such patients, we will compare disease evolution between the groups that developed or failed to develop CD4+ T cell responses to neoepitopes. We expect to obtain information as to whether the convergence of drug and immune pressure influences mutations leading to immune escape or drug resistance. The information to be obtained may help develop immune strategies that could be applied to enhance the immune response against mutant HIV-1 and fight the emergence of Pi-resistant HIV-1 strains. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R03
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    54000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:54000\
  • Funding Mechanism
  • Study Section
    AIP
  • Study Section Name
    AIDS Immunology and Pathogenesis Study Section
  • Organization Name
    UNIVERSITY OF SAO PAULO
  • Organization Department
  • Organization DUNS
    899159982
  • Organization City
    SAO PAULO
  • Organization State
  • Organization Country
    BRAZIL
  • Organization Zip Code
  • Organization District
    BRAZIL